Meier Hsu, MS

Research Biostatistician
Office Phone:
646-735-8050
Office Fax:
646-735-0010
E-mail:
hsum1@mskcc.org

Current Research Interests

Ms. Hsu primarily collaborates on projects in the area of colorectal cancer prevention involving the Adenoma Prevention with Celecoxib (APC) placebo-controlled clinical trial, with Dr. Zauber. She has worked on projects that explore the importance of genetic variants of NSAID metabolizing enzymes for dose-related anti-tumor response or toxicity related to celecoxib. She is currently involved with planned secondary analyses examining the use of statin drugs and other concomitant medications on the risk of adenoma recurrence.

Ms. Hsu also collaborates on numerous clinical projects with members of the department within the breast, lung, and gastrointestinal services, as well as within the department of radiation oncology. Ms. Hsu's research interests include methods for survival analysis particularly for data with interval censoring, time-dependent and repeated measurements. She is also interested in the assessment of appropriate endpoints for clinical trials.

Publications by Meier Hsu

Selected Publications

  1. Chan AT, Zauber AG, Hsu M, Breazna A, Hunter DJ, Rosenstein RB, Eagle CJ, Hawk ET, Bertagnolli MM.Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology. 2009 Jun;136(7):2127-2136.e1. Epub 2009 Feb 21. [PubMed Abstract]
  2. Karam AK, Hsu M, Patil S, Stempel M, Traina TA, Ho AY, Cody HS, Port ER, Morrow M, Gemignani ML. Predictors of completion axillary lymph node dissection in patients with positive sentinel lymph nodes. Ann Surg Oncol. 2009 Jul;16(7):1952-8. Epub 2009 Apr 18. [PubMed Abstract]
  3. Pugliese MS, Karam AK, Hsu M, Stempel MM, Patil SM, Ho AY, Traina TA, Van Zee KJ, Cody HS 3rd, Morrow M, Gemignani ML. Predictors of Completion Axillary Lymph Node Dissection in Patients With Immunohistochemical Metastases to the Sentinel Lymph Node in Breast Cancer. Ann Surg Oncol. 2009 Dec 22. [Epub ahead of print] [PubMed Abstract]
  4. Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, Miller VA, Ladanyi M. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008 Sep 15;14(18):5731-4. [PubMed Abstract]